Crow MK, Ronnblom L. Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases. Lupus Science & Medicine 2018;5:e000276. doi: 10.1136/lupus-2018-000276
The authors want to alert readers to the following two errors identified in the published version.
At page 4 (column 1, 2nd sentence of last paragraph), the sentence should read as: “Young women (35–44 years) with SLE have a 50-fold increased risk of vascular complications…”
In Table 1, the row under the drug “Anifrolumab” states that the drug is at Phase II for Sjögren’s syndrome. This has been stated incorrectly and has been removed. The updated Table 1 is now available below:
Table 1.
Therapeutic agents targeting components of the type I IFN pathway and in clinical development for IFN-driven diseases
| Drug | Drug MOA | Development status | Disease |
| RSLV132 | RNA hydrolysis | Phase II | Systemic lupus erythematosus Sjögren's syndrome |
| SM101 | Anti–immune complex | Phase II | Systemic lupus erythematosus Lupus nephritis |
| BIIB059 | Anti-BDCA2 (pDCs) | Phase II | Systemic lupus erythematosus |
| MEDI-7734 | Anti-ILT7 (pDCs) | Phase I | Dermatomyositis Polymyositis Systemic sclerosis Sjögren's syndrome Systemic lupus erythematosus |
| JNJ-55920839 | Anti–IFN-α/ω | Phase I | Systemic lupus erythematosus |
| AGS-009 | Anti–IFN-α | Phase I* | Systemic lupus erythematosus |
| IFN-α-kinoid | Anti–IFN-α | Phase II | Dermatomyositis |
| Phase II | Systemic lupus erythematosus | ||
| Anifrolumab | Anti-IFNAR1 | Phase II | Lupus nephritis |
| Phase III | Systemic lupus erythematosus | ||
| Baricitinib† | JAK1/JAK2 inhibitor | Phase II | Systemic lupus erythematosus |
| PF-04965842 | JAK1 inhibitor | Phase II | Systemic lupus erythematosus |
*Development status unknown.
†European Medicines Agency approved for rheumatoid arthritis.
IFN, interferon; IFNAR1, type I interferon alpha receptor subunit 1; ILT7, immunoglobulin-like transcript 7; JAK, Janus kinase; MOA, mechanism of action; pDCs, plasmacytoid dendritic cell.
In the legend of figure 1, the term ‘interferon-stimulating genes’ appears. The correct term is ‘interferon-stimulated genes’.
Figure 1.
The role of IFN in viral infection over time. cDC, conventional dendritic cell; IFN, interferon; IL, interleukin; ISG, interferon-stimulated genes; pDC, plasmacytoid dendritic cells; PD-L1, programmed death ligand 1; PRR, pattern recognition receptor. Left panel adapted from Crouse J et al 9; right panel adapted from Zuniga EI et al 10 (Reprinted by permission from Springer Customer Service Centre GmbH: Springer Nature, Nature Reviews Immunology; Regulation of antiviral T cell responses by type I interferons. Crouse J, Kalinke U, Oxenius A, © 2015. Republished with permission of Annual Reviews, from Innate and Adaptive Immune Regulation During Chronic Viral Infections, Zuniga EI, Macal M, Lewis GM, et al, Vol. 2, © 2015; permission conveyed through Copyright Clearance Center).